The no-reflow phenomenon in the coronary circulation.
The no-reflow phenomenon is a poorly understood complication of percutaneous coronary intervention in which diminished blood flow to distal microvascular beds persists despite the successful treatment of the occlusive lesion from the epicardial coronary artery or arteries. In this contemporary review we endeavour to discuss the pathophysiology of coronary no-reflow, understand the predictors and describe current pharmacological and mechanical strategies to prevent and treat coronary no-reflow.
Kiernan
Thomas J
TJ
Division of Interventional Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. tjkiernan@partners.org
Ruggiero
Nicholas J
NJ
Bernal
Juan M
JM
Don
Creighton W
CW
Witzke
Christian
C
Kiernan
Gareth D
GD
Cubeddu
Roberto J
RJ
Yan
Bryan P
BP
D000241:Adenosine / Q000627:therapeutic use; D000818:Animals; D003326:Coronary Circulation; D004110:Diltiazem / Q000627:therapeutic use; D006801:Humans; D009529:Nicardipine / Q000627:therapeutic use; D020108:Nicorandil / Q000627:therapeutic use; D009599:Nitroprusside / Q000627:therapeutic use; D054318:No-Reflow Phenomenon / Q000188:drug therapy* / Q000503:physiopathology* / Q000628:therapy; D019736:Prostheses and Implants; D014665:Vasodilator Agents / Q000627:therapeutic use; D014700:Verapamil / Q000627:therapeutic use
D014665:Vasodilator Agents; D009599:Nitroprusside; D020108:Nicorandil; D014700:Verapamil; D009529:Nicardipine; D004110:Diltiazem; D000241:Adenosine